- Joined
- Mar 24, 2006
- Messages
- 623
- Reaction score
- 2
I have to give a 10 minute overview of a review article in my physiology class that pertains specifically to the respiratory system. For me, one of the most complicated aspects of the respiratory system is how ventilation is driven and how disease states and medications affect ventilatory drive.
While investigating this topic I came across the drug doxapram. While it looks like it is only used in a limited fashion, I thought that an explanation of how the drug works would be a great way to explain respiratory drive.
Thoughts? Any comments about its use?
http://www.ncbi.nlm.nih.gov/pubmed/...nel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
While investigating this topic I came across the drug doxapram. While it looks like it is only used in a limited fashion, I thought that an explanation of how the drug works would be a great way to explain respiratory drive.
Thoughts? Any comments about its use?
http://www.ncbi.nlm.nih.gov/pubmed/...nel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
CNS Drug Rev. 2006 Fall-Winter;12(3-4):236-49.
A new look at the respiratory stimulant doxapram.
Yost CS.
Department of Anesthesia and Perioperative Care, University of California at San Francisco, San Francisco, California 94143, USA. [email protected]
A number of life-threatening clinical disorders may be amenable to treatment with a drug that can stimulate respiratory drive. These include acute respiratory failure secondary to chronic obstructive pulmonary disease, post-anesthetic respiratory depression, and apnea of prematurity. Doxapram has been available for over forty years for the treatment of these conditions and it has a low side effect profile compared to other available agents. Generally though, the use of doxapram has been limited to these clinical niches involving patients in the intensive care, post-anesthesia care and neonatal intensive care units. Recent basic science studies have made considerable progress in understanding the molecular mechanism of doxapram's respiratory stimulant action. Although it is unlikely that doxapram will undergo a clinical renaissance based on this new understanding, it represents a significant advance in our knowledge of the control of breathing.